{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6"}]}],"title":"Age >=65 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8"}]}],"title":"Advanced disease*"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"}]}],"title":"History of FN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3"}]}],"title":"No antibiotic prophylaxis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3"}]}],"title":"Poor performance and/or nutritional status"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8"}]}],"title":"Female gender"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9"}]}],"title":"Hb < 12 g/dL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9"}]}],"title":"Renal, CV, or liver disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"650"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\n\\* Advanced disease is defined as Stage IV (Stage III or IV if multiple myeloma) AND prior chemotherapy in metastatic setting CV: cardiovascular; EORTC: European Organization for Research and Treatment in Cancer; FN: febrile neutropenia; Hb: hemoglobin","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Patients with chemotherapy risk 10-20% in evaluable sample","reportingStatus":"POSTED","timeFrame":"Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"Percentage of Patients With Each EORTC-identified Risk Factors for FN in Patients With Chemotherapy Risk 10-20% at Baseline","type":"PRIMARY","unitOfMeasure":"percentage of patients"}